Related Experiment Video
Updated: Sep 23, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Progressive Conduction System Disease Preceding Hypertrophy in IVS4 + 919G > A Fabry Variant: a Population-based
Wei-Hsin Chung1,2, Cheng-Chang Tung1,2, Ting-Yuan Liu3,4
1Taichung Municipal Geriatric Rehabilitation General Hospital, Taichung, Taiwan.
Background:
The IVS4 + 919G > A variant is the most prevalent late-onset Fabry variant in East Asian populations, but its electrophysiological trajectory remains incompletely defined.
Methods:
From a regional genetic screening program, 905 IVS4 + 919G > A carriers were identified among 457,581 patients and matched 1:2 to controls by age and sex. Electrocardiographic (ECG) parameters were compared across decades, and echocardiography correlated structural changes with ECG findings.
Results:
The cumulative prevalence of IVS4 + 919G > A was 0.198%. Age-specific prevalence in females was ∼2.5-fold higher than in males (0.11-0.15%), without significant change throughout different age categories. Female carriers demonstrated the catch-up phenomenon after the age of 60. Males exhibited a 9-fold risk of right bundle branch block (RBBB) and pacemaker implantation (PPM) compared with male controls (RBBB, HR 9.286, 95% CI 5.16-16.70, P < 0.001; PPM, HR 9.197, 95% CI 2.88-29.31, P < 0.001), and this precedes the onset of echocardiographic left ventricular hypertrophy. Risk of stroke and atrial fibrillation (HR 1.435, 95% CI 0.69-2.96, P = 0.289) was similar between male carriers and controls. PR interval was not shortening and prolongs instead. Combining left ventricular hypertrophy with conduction abnormalities, ECG detection achieved 88% sensitivity, exceeding echocardiographic criteria alone (51.5%).
Conclusions:
IVS4 + 919G > A variant is characterized by a progressive electrical phenotype dominated by conduction system disease preceding hypertrophy without excess major arrhythmic events. Electrocardiographic surveillance and phenotype-based risk stratification may be more informative than structural assessment alone for identifying individuals at risk of device therapy.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Conduction System of the Heart
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
Conduction System of the Heart
This system relies on the unique properties of nodal and Purkinje cells:...

